Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
J Med Chem ; 64(9): 5577-5592, 2021 05 13.
Article in English | MEDLINE | ID: mdl-33886285

ABSTRACT

The central melanocortin-3 and melanocortin-4 receptors (MC3R, MC4R) are key regulators of body weight and energy homeostasis. Herein, the discovery and characterization of first-in-class small molecule melanocortin agonists with selectivity for the melanocortin-3 receptor over the melanocortin-4 receptor are reported. Identified via "unbiased" mixture-based high-throughput screening approaches, pharmacological evaluation of these pyrrolidine bis-cyclic guanidines resulted in nanomolar agonist activity at the melanocortin-3 receptor. The pharmacological profiles at the remaining melanocortin receptor subtypes tested indicated similar agonist potencies at both the melanocortin-1 and melanocortin-5 receptors and antagonist or micromolar agonist activities at the melanocortin-4 receptor. This group of small molecules represents a new area of chemical space for the melanocortin receptors with mixed receptor pharmacology profiles that may serve as novel lead compounds to modulate states of dysregulated energy balance.


Subject(s)
Guanidine/metabolism , Pyrrolidines/chemistry , Receptor, Melanocortin, Type 3/agonists , Algorithms , Animals , Drug Evaluation, Preclinical , Energy Metabolism/drug effects , Guanidine/analogs & derivatives , Guanidine/pharmacology , Guanidine/therapeutic use , High-Throughput Screening Assays , Humans , Mice , Mice, Knockout , Protein Isoforms/agonists , Protein Isoforms/genetics , Protein Isoforms/metabolism , Pyrrolidines/metabolism , Pyrrolidines/pharmacology , Pyrrolidines/therapeutic use , Receptor, Melanocortin, Type 3/genetics , Receptor, Melanocortin, Type 3/metabolism , Small Molecule Libraries/chemistry , Small Molecule Libraries/metabolism , Small Molecule Libraries/pharmacology , Small Molecule Libraries/therapeutic use , Structure-Activity Relationship
2.
Methods Mol Biol ; 1700: 293-318, 2018.
Article in English | MEDLINE | ID: mdl-29177837

ABSTRACT

The resistance nodulation cell division (RND) family of proteins are inner membrane transporters that associate with periplasmic adaptor proteins and outer membrane porins to affect substrate transport from the cytosol and periplasm in Gram-negative bacteria. Various structurally diverse compounds are substrates of RND transporters. Along with their notable role in antibiotic resistance, these transporters are essential for niche colonization, quorum sensing, and virulence as well as for the removal of fatty acids and bile salts. As such, RNDs are an attractive target for antimicrobial development. However, while enhancing the utility of antibiotics with an RND inhibitor is an appealing concept, only a small core of chemotypes has been identified as efflux pump inhibitors (EPIs). Thus, our key objective is the development and validation of an efflux profiling and discovery strategy for RND model systems. Here we describe a flow cytometric dye accumulation assay that uses fluorescein diacetate (FDA) to interrogate the model Gram-negative pathogens Escherichia coli, Franscisella tularensis, and Burkholderia pseudomallei. Fluorochrome retention is increased in the presence of known efflux inhibitors and in RND deletion strains. The assay can be used in a high-throughput format to evaluate efflux of dye-substrate candidates and to screen chemical libraries for novel EPIs. Triaged compounds that inhibit efflux in pathogenic strains are tested for growth inhibition and antibiotic potentiation using microdilution culture plates in a select agent Biosafety Level-3 (BSL3) environment. This combined approach demonstrates the utility of flow cytometric analysis for efflux activity and provides a useful platform in which to characterize efflux in pathogenic Gram-negative bacteria. Screening small molecule libraries for novel EPI candidates offers the potential for the discovery of new classes of antibacterial compounds.


Subject(s)
Anti-Bacterial Agents/pharmacology , Fluoresceins/metabolism , Gram-Negative Bacteria/growth & development , Membrane Transport Proteins/isolation & purification , Small Molecule Libraries/pharmacology , Bacterial Proteins/isolation & purification , Bacterial Proteins/metabolism , Burkholderia pseudomallei/growth & development , Burkholderia pseudomallei/metabolism , Drug Evaluation, Preclinical , Drug Resistance, Multiple, Bacterial , Escherichia coli/growth & development , Escherichia coli/metabolism , Flow Cytometry , Francisella tularensis/growth & development , Francisella tularensis/metabolism , Gram-Negative Bacteria/metabolism , Membrane Transport Proteins/metabolism , Substrate Specificity
3.
ACS Comb Sci ; 18(1): 51-64, 2016 Jan 11.
Article in English | MEDLINE | ID: mdl-26651386

ABSTRACT

The hypothesis in the current study is that the simultaneous direct in vivo testing of thousands to millions of systematically arranged mixture-based libraries will facilitate the identification of enhanced individual compounds. Individual compounds identified from such libraries may have increased specificity and decreased side effects early in the discovery phase. Testing began by screening ten diverse scaffolds as single mixtures (ranging from 17,340 to 4,879,681 compounds) for analgesia directly in the mouse tail withdrawal model. The "all X" mixture representing the library TPI-1954 was found to produce significant antinociception and lacked respiratory depression and hyperlocomotor effects using the Comprehensive Laboratory Animal Monitoring System (CLAMS). The TPI-1954 library is a pyrrolidine bis-piperazine and totals 738,192 compounds. This library has 26 functionalities at the first three positions of diversity made up of 28,392 compounds each (26 × 26 × 42) and 42 functionalities at the fourth made up of 19,915 compounds each (26 × 26 × 26). The 120 resulting mixtures representing each of the variable four positions were screened directly in vivo in the mouse 55 °C warm-water tail-withdrawal assay (ip administration). The 120 samples were then ranked in terms of their antinociceptive activity. The synthesis of 54 individual compounds was then carried out. Nine of the individual compounds produced dose-dependent antinociception equivalent to morphine. In practical terms what this means is that one would not expect multiexponential increases in activity as we move from the all-X mixture, to the positional scanning libraries, to the individual compounds. Actually because of the systematic formatting one would typically anticipate steady increases in activity as the complexity of the mixtures is reduced. This is in fact what we see in the current study. One of the final individual compounds identified, TPI 2213-17, lacked significant respiratory depression, locomotor impairment, or sedation. Our results represent an example of this unique approach for screening large mixture-based libraries directly in vivo to rapidly identify individual compounds.


Subject(s)
Analgesics/chemistry , Analgesics/pharmacology , Drug Evaluation, Preclinical/methods , Piperazines/chemistry , Piperazines/pharmacology , Pyrrolidines/chemistry , Pyrrolidines/pharmacology , Analgesics/chemical synthesis , Analgesics/therapeutic use , Animals , Combinatorial Chemistry Techniques/methods , High-Throughput Screening Assays/methods , Male , Mice , Mice, Inbred C57BL , Pain/drug therapy , Piperazines/chemical synthesis , Piperazines/therapeutic use , Pyrrolidines/chemical synthesis , Pyrrolidines/therapeutic use , Small Molecule Libraries/chemical synthesis , Small Molecule Libraries/chemistry , Small Molecule Libraries/pharmacology , Small Molecule Libraries/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL